ELX-02 is under clinical development by Eloxx Pharmaceuticals and currently in Phase II for Alport Syndrome. According to GlobalData, Phase II drugs for Alport Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ELX-02 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ELX-02 is under development for the treatment of nonsense genetic diseases including mucopolysaccharidosis I (Hurler Syndrome), cystic fibrosis, Alport syndrome, autosomal dominant polycystic kidney disease, Duchenne muscular dystrophy. The drug candidate is a synthetic aminoglycoside administered through subcutaneous route and inhalational route. It optimizes ribosomal read-through of premature termination codons (PTC). It acts by targeting CFTR. It was also under development for cystinosis, nephropathic cystinosis, cystic fibrosis, Rett syndrome and other genetic diseases. It is being developed based on TURBO-ZM technology platform.
Eloxx Pharmaceuticals overview
Eloxx Pharmaceuticals (Eloxx), formerly Sevion Therapeutics Inc, is a clinical-stage biopharmaceutical company that develops novel RNA-modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. The company’s lead product candidate, ELX-02, is in Phase II clinical trials for the treatment of cystic fibrosis. Its preclinical candidates include novel ERSG drug candidates for the treatment of autosomal dominant polycystic kidney disease (ADPKD) and Usher syndrome. The company has a subsidiary in Israel. Eloxx is headquartered in Watertown, Massachusetts, the US.
For a complete picture of ELX-02’s drug-specific PTSR and LoA scores, buy the report here.